Mycophenolate Mofetil

證據等級: L5

預測適應症: 10 個

Mycophenolate Mofetil: From Transplant Rejection Prophylaxis to HIV Infectious Disease

One-Sentence Summary

Mycophenolate mofetil (MMF) is an inosine monophosphate dehydrogenase (IMPDH) inhibitor established as an immunosuppressant for preventing organ transplant rejection. The TxGNN model predicts it may be effective against HIV infectious disease, with 10 clinical trials and 20 publications currently supporting this direction — though several trials ended in WITHDRAWN, UNKNOWN, or TERMINATED status.

Quick Overview

Item	Content
Original Indication	Prevention of organ transplant rejection (well-established clinical use; not captured in this evidence pack, as no license/indication records were returned)
Predicted New Indication	HIV infectious disease
TxGNN Prediction Score	99.86%
Evidence Level	L2
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DrugBank query pending). Based on known pharmacology, mycophenolate mofetil is metabolized to mycophenolic acid, an IMPDH inhibitor that blocks the de novo purine (guanosine) synthesis pathway required for lymphocyte proliferation. Its efficacy in preventing transplant rejection is well established.

Mechanistically, IMPDH inhibition also depletes intracellular deoxyguanosine triphosphate (dGTP) pools in activated T cells — the same nucleotide pool HIV reverse transcriptase depends on. This provides a biochemical rationale for using MMF as an adjunct to NRTIs (e.g., abacavir, didanosine), where MPA has been shown in vitro to potentiate antiretroviral activity. However, this is a double-edged mechanism: the same immunosuppressive property that prevents transplant rejection could further weaken immune function in an already immunocompromised HIV population, which is reflected in the mixed and often inconclusive clinical trial record below.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00021489	Phase 2	Withdrawn (n=0)	0	Designed to test MMF safety/tolerability + antiretroviral activity added to abacavir in treatment-experienced HIV patients; no data generated
NCT00247494	Phase 4	Unknown	90	Substudy of MAN2; evaluated MMF's effect on cardiovascular surrogate markers in HIV-1 patients; results unpublished
NCT00120419	Phase 4	Unknown	90	MAN2 study — MMF in ART-naive chronic HIV-1 patients, assessing CD4+ decline, plasma HIV-1 RNA, and safety; results unpublished
NCT00038272	Phase 1/2	Completed	56	Randomized, double-blind, placebo-controlled: DAPD (amdoxovir) vs DAPD+MMF in treatment-experienced subjects
NCT01453192	Phase 3	Completed	27	Renal transplant follow-up in HIV-1 patients under raltegravir-based regimen; MMF used as standard anti-rejection agent, not to treat HIV
NCT00009009	Phase 2	Completed	10	Feasibility/safety of renal transplantation (with MMF as immunosuppressant) in HIV-infected patients with ESRD
NCT00112593	N/A	Completed	5	Allogeneic HSCT with fludarabine/TBI conditioning plus cyclosporine+MMF for mixed chimerism induction in HIV-1 patients
NCT02793544	Phase 2	Completed	80	HLA-mismatched unrelated donor BMT with post-transplant cyclophosphamide, sirolimus, MMF for GVHD prophylaxis (hematologic malignancies, not HIV-specific)
NCT06869265	Phase 2	Recruiting	56	Thiotepa/busulfan/fludarabine conditioning for haplo-HSCT in high-risk AML; MMF as part of GVHD prophylaxis, unrelated to HIV indication
NCT01288131	Phase 3	Terminated	8	Cyclosporine+MMF vs cyclophosphamide+prednisolone for anti-EPO PRCA; not an HIV trial

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15213566	2004	Randomized pilot study	J Acquir Immune Defic Syndr	MMF vs continued HAART during structured treatment interruption; assessed immune response and viral load in lymphatic tissue
15353978	2004	Comparative study	AIDS	HAART with vs without MMF in treatment-naive HIV-1 patients; examined effect on plasma HIV-1 RNA decay and latent reservoir
16379601	2005	Cohort	AIDS Res Hum Retroviruses	No detrimental immunological effects observed when combining MMF with HAART in treatment-naive acute/chronic HIV-1 patients
12352149	2002	Cohort	J Acquir Immune Defic Syndr	Adding MMF to abacavir-containing ART depleted intracellular dGTP and reduced plasma HIV-1 RNA in 5 patients
15871638	2005	PK/PD study	Clin Pharmacokinet	Pharmacokinetics/pharmacodynamics of low-dose MMF combined with abacavir, efavirenz, nelfinavir in HIV patients
15355127	2004	PK/PD study	Clin Pharmacokinet	Effect of MMF on pharmacokinetics of antiretroviral drugs and intracellular nucleoside triphosphate pools
11391161	2001	Pilot study	J Acquir Immune Defic Syndr	Open-label pilot in 7 multidrug-resistant AIDS patients: MMF + abacavir/ddI/amprenavir/ritonavir; well tolerated, no significant HIV RNA decline reported
17017956	2006	Review	Curr Top Med Chem	Reviews immunosuppressive drugs (including MMF) as adjuncts targeting chronic immune activation in HIV disease progression
17885292	2007	Comparative study	AIDS	Safety, tolerability, and antiretroviral activity of amdoxovir (DAPD) with or without MMF in drug-resistant HIV infection
16515490	2006	Review	Curr Pharm Des	Discusses "virostatics" (including MMF) as a strategy to target residual HIV replication in cellular reservoirs alongside HAART

Germany Market Information

Mycophenolate mofetil is currently not marketed in Germany under this evidence pack's data source (0 authorizations, no license records available). No German product-level dosage form or approved indication text could be extracted.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data are not currently available in this evidence pack (DDI query returned no results).

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence level is L2, but the strongest directly-relevant trials for MMF-in-HIV are either withdrawn (0 enrolled), of unknown/unpublished outcome (MAN2, cardiovascular substudy), or small pilot studies without confirmed efficacy — no trial demonstrates a clear positive antiviral benefit. Combined with a Blocking data gap on TFDA/BfArM warnings and contraindications (required for any S1 safety evaluation) and a High-severity gap on mechanism of action, this candidate cannot yet advance past the research-question stage.

To proceed, the following is needed:

Resolve DG001 (Blocking): retrieve and parse official package insert warnings/contraindications before any safety-stage review
Resolve DG002 (High): confirm MOA via DrugBank API to support mechanistic-link analysis
Follow up on unpublished/unknown-status trials (NCT00247494, NCT00120419) to determine whether results exist
Formal DDI assessment against antiretroviral regimens (abacavir, NRTIs), given PK interaction signals in the literature (PMID 15355127, 15871638)
Explicit risk-benefit assessment of adding an immunosuppressant in an immunocompromised HIV population before any further development
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.